NCT07276815招募中不适用
Gathering of Results in Eligible Asian Obese Populations About Safety and Effectiveness of Overstitch ESG Trial
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 136
- 试验地点
- 1
- 主要终点
- %TBWL (Defined as the percentage of total body weight loss)
研究概览
简要总结
To demonstrate the safety and efficacy of OverStitch NXT Endoscopic Suture System for endoscopic sleeve gastroplasty（ESG） in obese populations to support the registration of OverStitch NXT for ESG indication.
详细描述
The study is a prospective, multicenter, randomized controlled trial
This study is planned to be conducted at 10 sites, with each center initially enrolling 2 roll-in cases (totaling 20 cases). After each site completes the enrollment of its roll-in cases, the remaining subjects will be randomly divided into two groups (the treatment group and the control group) via a central randomization system. Each group will ultimately enroll 58 subjects, resulting in a total sample size of 136 for the study.
Roll-in Cases: ESG combined with lifestyle management for 12 months. treatment group: ESG combined with lifestyle management for 12 months. control group: Lifestyle management alone for 12 months, followed by evaluation. Eligible participants may undergo ESG afterward.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or older, or subjects who have reached the legal age for signing informed consent in accordance with local laws and regulations.
- •BMI ≥ 32.5 kg/m²; or BMI ≥ 27.5 kg/m² combined with type 2 diabetes mellitus (regardless of the effectiveness of medical treatment for type 2 diabetes); or BMI between 27.5 kg/m² and 32.5 kg/m² with ineffective medical weight loss or combined with other obesity-related diseases for which medical treatment is ineffective.
- •Willing to comply with the long-term strict dietary restrictions required by the surgery.
- •Capable of providing informed consent, able to complete all routine follow-up visits, and willing to abide by the protocol requirements, including signing the informed consent form, completing relevant examinations, and receiving dietary counseling.
- •Females of childbearing potential (i.e., premenopausal or not sterilized) must agree to use adequate contraceptive measures.
排除标准
- •History of foregut or gastrointestinal (GI) surgery (except uncomplicated cholecystectomy or appendectomy)
- •Prior gastrointestinal surgery with sequelae, i.e. obstruction, and/or adhesive peritonitis or known abdominal adhesions.
- •Prior open or laparoscopic bariatric surgery.
- •Prior surgery of any kind on the esophagus or any type of hiatal hernia surgery.
- •Any inflammatory disease of the gastrointestinal tract including severe (LA Grade C or D) esophagitis, gastric ulceration, duodenal ulceration, specific inflammation such as Crohn's disease, and the doctor judges that it may affect the operation or efficacy of ESG.
- •Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresia or stenosis.
- •History of gastrointestinal stromal tumors, gastrointestinal cancer, low-grade or high-grade gastric intraepithelial neoplasia, or familial or non-familial adenomatous polyposis syndrome.
- •Gastric masses or untreated gastric polyps with a diameter > 1 cm.
- •Hiatal hernia (Z-line displacement above the diaphragm > 4 cm) or severe/refractory gastroesophageal reflux symptoms, which the physician judges may affect the performance or prognosis of ESG.
- •Structural abnormalities of the esophagus or pharynx that may impede endoscopic passage (e.g., strictures or diverticula), which the physician judges may affect the performance or prognosis of ESG.
- •Gastrointestinal motility disorders (e.g., achalasia, severe esophageal motility disorders, gastroparesis, or intractable constipation), which the physician judges may affect the performance or prognosis of ESG.
- •Evidence of untreated psychiatric or eating disorders, such as major depression, schizophrenia, substance abuse, binge eating disorder, or bulimia nervosa.
- •Coagulopathy with INR > 1.5 that cannot be corrected (per physician's judgment) or requirement for continuous full anticoagulant therapy, and/or any underlying diseases associated with high bleeding risk.
- •Insulin-dependent diabetes mellitus (type 1 or type 2), or high likelihood of requiring insulin therapy within the next 12 months.
- •Decompensated cirrhosis, or acute/chronic liver dysfunction that the physician judges make the subject unsuitable for ESG treatment.
- •Diagnosis of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma) or immunocompromise, which the physician assesses may affect the performance or prognosis of ESG.
- •Known history of endocrine diseases affecting body weight (e.g., Cushing's syndrome, uncontrolled hypothyroidism, or hyperthyroidism), which the physician assesses may affect the performance or prognosis of ESG.
- •Anemia: Hemoglobin (Hgb) < 110 g/L for females; Hgb < 120 g/L for males.
- •Any other medical conditions precluding elective endoscopy, such as poor general health, history of severe renal, hepatic, cardiac, and/or pulmonary diseases, and/or severe or uncontrolled psychiatric illnesses or abnormalities that may impair the patient's ability to understand or comply with follow-up visits and lifestyle interventions.
- •Active psychological issues as determined by a psychologist or psychiatrist, precluding participation in lifestyle modification programs.
- •Unwillingness to participate in the established medically supervised dietary and behavioral modification programs, as well as routine medical follow-up.
- •Daily treatment with prescribed high-dose aspirin (> 80 mg per day), non-steroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, anticoagulants, corticosteroids, immunosuppressants, or other gastric irritant medications.
- •Interval use of medications that may be affected by changes in gastric emptying (e.g., antiepileptic drugs or antiarrhythmic drugs).
- •Inability or unwillingness to take prescribed proton pump inhibitor (PPI) medications.
- •Current use of weight loss medications or other weight loss devices or use within the past 90 days.
- •Current participation in a clinical trial involving investigational drugs or devices, or participation in such a trial within 30 days prior to enrollment in this study.
- •Use of intragastric devices within 30 days prior to this study, which the physician assesses may affect the performance or prognosis of ESG.
- •Unwillingness to avoid any reconstructive and/or plastic surgeries that may affect body weight during the study (e.g., mammoplasty, liposuction).
- •Other conditions deemed unsuitable for endoscopy or ESG treatment by the investigator, including but not limited to conditions that the investigator believes may expose the subject to significant risks, confound study results, increase risks associated with endoscopy and/or endoscopic procedures, or substantially interfere with the subject's participation in the study.
- •Pregnancy, lactation, or intention to become pregnant during the study (for females of childbearing potential).
研究组 & 干预措施
Roll-in Cases
Other
ESG combined with lifestyle management for 12 months
干预措施: OverStitch NXT Endoscopic Suture System (Device)
Treatment group
Experimental
ESG combined with lifestyle management for 12 months.
干预措施: OverStitch NXT Endoscopic Suture System (Device)
Control group
No Intervention
Lifestyle management alone for 12 months, followed by evaluation. Eligible participants may undergo ESG afterward.
结局指标
主要结局
%TBWL (Defined as the percentage of total body weight loss)
时间窗: At 12 months after the intervention.
%TBWL is defined as the percentage of total body weight loss
The response rate at the 12th month after the intervention
时间窗: At 12 months after the intervention
Response is defined as having a percentage of total body weight loss (%TBWL) of ≥ 5%
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy ProceduresNCT07271303Shanghai Jiao Tong University School of Medicine74
招募中
1 期
The safety of Endoscopic Sleeve Gastroplasty for Japanese obesity patientsobesity patients with BMI more than 27kg/m2Obesity, Endoscopic therapy, Bariatric surgeryJPRN-jRCTs032200049Sumiyama Kazuki20
招募中
3 期
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn's Disease2023-504737-41-00Janssen - Cilag International219
尚未招募
不适用
Effects on Non-Alcoholic Steato-Hepatitis (NASH) liver disease, obesity-associated metabolicdisturbances, weight loss, safety and quality of life in adults with NASH and obesity undergoing endoscopic sleeve gastroplasty.on-alcoholic fatty liver diseaseNon-alcoholic fatty liver diseaseMetabolic and Endocrine - Metabolic disordersDiet and Nutrition - ObesityOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonobesityACTRN12618001888257Dr Damian Harding (Chief researcher)10
已完成
不适用
EFFICACY OF THE SLEEVE GASTROPLASTY WITH THE ENDOSCOPIC SYSTEM OVERSTICH SX ON WEIGHT LOSS AND REDUCTION OF CO-MORBIDITY FOR OBESE PATIENTSObesityNCT05072067Clinique du Trocadéro120